Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)
Titel:
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)
Auteur:
Zeidner, Joshua F. Foster, Matthew C. Blackford, Amanda L. Litzow, Mark R. Morris, Lawrence E. Strickland, Stephen A. Lancet, Jeffrey E. Bose, Prithviraj Levy, M. Yair Tibes, Raoul Gojo, Ivana Gocke, Christopher D. Rosner, Gary L. Little, Richard F. Wright, John J. Doyle, L. Austin Smith, B. Douglas Karp, Judith E.